Rovalpituzumab tesirine: Additional Phase I/II data

Data from 60 evaluable patients with recurrent SCLC who failed >=1 prior systemic therapy in the open-label, dose-escalation, U.S. Phase I/II SCRX16-001 trial showed that IV Rova-T every 3 weeks led

Read the full 317 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE